Latest Strategy News

Red Hill Minerals reports a profitable FY25 with robust royalty income from the Onslow Iron Project, declaring a fully franked final dividend of 6.5 cents per share.

Resimac Group has successfully settled a A$1 billion non-conforming residential mortgage backed securities transaction, marking its second such bond issuance this year. The deal attracted strong domestic and offshore investor interest, reinforcing Resimac’s diversified funding strategy.

QMines Limited has launched a significant 5,000m drilling campaign at its Mount Mackenzie gold and silver project, aiming to unlock substantial resource growth potential following a recent resource upgrade.

Leo Lithium has announced a significant $330 million return to shareholders in 2025, following the termination of its asset acquisition strategy and a decision to monetise remaining assets.

Challenger Limited has announced the Dividend Reinvestment Plan (DRP) issue price for its final 2025 dividend at $8.3615 per share, with a modest 2% participation rate leading to the issuance of approximately 266,000 new shares.

Blue Star Helium has decided not to exercise its purchase option on key Colorado helium assets after thorough evaluation, signaling a strategic pivot in its growth approach.

Auravelle Resources reports standout high-grade gold results from its South Australian projects and outlines a robust exploration agenda targeting major gold deposits nearby.

Western Gold Resources has responded to ASX inquiries about recent unusual trading activity, disclosing partial assay results from its Gold Duke drilling program while affirming compliance with continuous disclosure rules.

Tempest Minerals has secured regulatory approval to begin Phase I drilling at its Halo prospect within the Yalgoo Project, targeting iron, copper, and gold. A heritage survey with the Badimia People is currently in progress, marking a key step toward unlocking the site's potential.

Neurizon Therapeutics has raised $5 million through an institutional placement to advance its lead ALS drug candidate NUZ-001 into a pivotal clinical trial, pending FDA clearance. The capital injection also supports manufacturing and pre-clinical development efforts.

Pathkey.AI has upgraded its TrialKey platform to include drug-level molecular and pharmacokinetic features, enhancing clinical trial predictions and opening doors to AI-driven drug discovery.

Litchfield Minerals has successfully raised $1.5 million through an oversubscribed placement and share purchase plan, fueling an ambitious 14-hole drilling campaign at its flagship Oonagalabi Project.